Moomoo AI 已提取核心信息
Johnson & Johnson (J&J) has announced a definitive agreement to acquire Ambrx Biopharma, Inc. in an all-cash transaction valued at approximately $2.0 billion. The acquisition, expected to close in the first half of 2024, will enhance J&J's oncology portfolio with Ambrx's proprietary antibody drug conjugates (ADCs) and synthetic biology technology platform. Ambrx's lead product candidate, ARX517, targets metastatic castration-resistant prostate cancer (mCRPC), and the company also has other clinical and preclinical programs for various cancer indications. J&J's Chairman and CEO, Joaquin Duato, discussed the strategic fit of the acquisition at the 42nd Annual Healthcare Conference hosted by JPMorgan, highlighting the potential of Ambrx's ADC technology and the significant market for mCRPC treatments. The transaction is subject to Ambrx shareholder approval, antitrust clearances, and other customary closing conditions. Upon completion, Ambrx's common stock will be delisted from the NASDAQ Global Select Market.
Johnson & Johnson (J&J) has announced a definitive agreement to acquire Ambrx Biopharma, Inc. in an all-cash transaction valued at approximately $2.0 billion. The acquisition, expected to close in the first half of 2024, will enhance J&J's oncology portfolio with Ambrx's proprietary antibody drug conjugates (ADCs) and synthetic biology technology platform. Ambrx's lead product candidate, ARX517, targets metastatic castration-resistant prostate cancer (mCRPC), and the company also has other clinical and preclinical programs for various cancer indications. J&J's Chairman and CEO, Joaquin Duato, discussed the strategic fit of the acquisition at the 42nd Annual Healthcare Conference hosted by JPMorgan, highlighting the potential of Ambrx's ADC technology and the significant market for mCRPC treatments. The transaction is subject to Ambrx shareholder approval, antitrust clearances, and other customary closing conditions. Upon completion, Ambrx's common stock will be delisted from the NASDAQ Global Select Market.
强生公司（J&J）宣布了一项最终协议，以价值约20亿美元的全现金交易收购Ambrx Biopharma, Inc.此次收购预计将于2024年上半年完成，将通过Ambrx的专有抗体药物偶联物（ADC）和合成生物学技术平台增强强生的肿瘤学产品组合。Ambrx的主要候选产品 ARX517 针对转移性去势抗性前列腺癌（mcRPC），该公司还针对各种癌症适应症还有其他临床和临床前项目。强生董事长兼首席执行官华金·杜阿托在摩根大通主办的第42届年度医疗保健会议上讨论了此次收购的战略契合度，重点介绍了Ambrx的ADC技术的潜力以及mcRPC治疗的巨大市场。该交易须经Ambrx股东批准、反垄断许可和其他惯例成交条件。完成后，Ambrx的普通股将从纳斯达克全球精选市场退市。
强生公司（J&J）宣布了一项最终协议，以价值约20亿美元的全现金交易收购Ambrx Biopharma, Inc.此次收购预计将于2024年上半年完成，将通过Ambrx的专有抗体药物偶联物（ADC）和合成生物学技术平台增强强生的肿瘤学产品组合。Ambrx的主要候选产品 ARX517 针对转移性去势抗性前列腺癌（mcRPC），该公司还针对各种癌症适应症还有其他临床和临床前项目。强生董事长兼首席执行官华金·杜阿托在摩根大通主办的第42届年度医疗保健会议上讨论了此次收购的战略契合度，重点介绍了Ambrx的ADC技术的潜力以及mcRPC治疗的巨大市场。该交易须经Ambrx股东批准、反垄断许可和其他惯例成交条件。完成后，Ambrx的普通股将从纳斯达克全球精选市场退市。
有用
没用